Advertisement
Screener

ORGANOGENESIS HOLDINGS INC. (ORGO) Current Income Tax Expense (Benefit)

1.5 / 5 stars · 25/86 Roast Me

ORGANOGENESIS HOLDINGS INC. Current Income Tax Expense (Benefit)

ORGANOGENESIS HOLDINGS INC. (ORGO) reported Current Income Tax Expense (Benefit) of $438.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Expense Statement › Income Tax

us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-26

  • ORGANOGENESIS HOLDINGS INC. current income tax expense (benefit) for fiscal 2025 was $438.00K, a 93.79% decline from fiscal 2024.
  • ORGANOGENESIS HOLDINGS INC. current income tax expense (benefit) for fiscal 2024 was $7.05M, a 105.27% increase from fiscal 2023.
  • ORGANOGENESIS HOLDINGS INC. current income tax expense (benefit) for fiscal 2023 was $3.44M, a 24.01% increase from fiscal 2022.
  • ORGANOGENESIS HOLDINGS INC. current income tax expense (benefit) for fiscal 2022 was $2.77M, a 222.09% increase from fiscal 2021.
Period endCurrent Income Tax Expense (Benefit) 12 month
2025-12-31$438.00K
10-K · filed 2026-02-26
2024-12-31$7.05M
10-K · filed 2026-02-26
2023-12-31$3.44M
10-K · filed 2026-02-26
2022-12-31$2.77M
10-K · filed 2025-02-27
2021-12-31$860.00K
10-K · filed 2024-02-29
2020-12-31$418.00K
10-K · filed 2023-03-01
2019-12-31$39.00K
10-K · filed 2022-03-01
2018-12-31-$102.00K
10-K · filed 2021-03-16
2017-12-31$276.00K
10-K · filed 2020-03-09
2016-12-31$65.00K
10-K · filed 2019-03-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
PepGen Inc. (PEPG)United States$0.186B-1.73
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50